Streetbeat News

NVAX

Novavax, Inc.

https://www.novavax.com

Industry

Biotechnology

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Open

7.14

Mkt cap

1.2B

Volume

High

7.33

P/E Ratio

-3.01

52-wk high

23.86

Low

6.81

Div yield

N/A

52-wk low

3.53

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted approvals for the COVID-19 vaccines Comirnaty, developed by Pfizer/BioNTech, and Nuvaxovid, developed by Novavax. This marks a significant step in the fight against COVID-19 and opens up new markets for both vaccines.

Portfolio Pulse from Charles Gross

February 09, 2024 | 11:55 am

Novavax Inc announced that its R21/Matrix-M malaria vaccine, developed with the University of Oxford and Serum Institute of India, received WHO prequalification based on Phase 3 trial results published in The Lancet. The vaccine showed a 75% reduction in symptomatic malaria cases in seasonal transmission areas and 68% efficacy in perennial regions among children aged 5-36 months. Priced at approximately $3 per dose, it's considered more affordable and accessible than GSK Plc's vaccine, with 25 million doses already produced for the current year.

Portfolio Pulse from Vandana Singh

February 02, 2024 | 5:41 pm

Novavax announced the publication of Phase 3 trial results for its R21/Matrix-M malaria vaccine in The Lancet, reporting a 75% efficacy when administered before the high transmission season in areas with highly seasonal malaria transmission.

Portfolio Pulse from Charles Gross

February 02, 2024 | 12:11 pm

Novavax (NYSE:NVAX) has seen a 3.5% increase in short interest since its last report, with 50.91 million shares sold short, representing 51.47% of its float. It would take about 4.95 days to cover all short positions. High short interest can indicate bearish market sentiment but can also be bullish if it leads to a short squeeze. Novavax's short interest is significantly higher than its peer group average of 9.76%.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 8:30 pm

Novavax has announced that its updated protein-based, non-mRNA COVID-19 vaccine is now available at vaccination centers in Taiwan. This marks a significant step for the company in expanding the global reach of its vaccine, which offers an alternative to mRNA vaccines.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 2:12 pm

Novavax is initiating a new cost reduction program aimed at further reducing R&D and SG&A expenses. The goal is to drive total expenses below $750 million for the year 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:33 pm

Novavax Inc (NASDAQ:NVAX) announced that its updated Covid-19 vaccine, Nuvaxovid XBB.1.5, received emergency use authorization in Taiwan. The Taiwan FDA approved the vaccine for individuals 12 years and older, based on non-clinical data showing functional immune responses to several variants. Novavax will supply the vaccine under an existing agreement, with availability expected at vaccination centers across Taiwan. Despite the news, NVAX shares were down 1.30% at $5.33.

Portfolio Pulse from Adam Eckert

December 18, 2023 | 2:43 pm

Novavax has received Emergency Use Authorization from the Taiwan Food and Drug Administration for its updated COVID-19 vaccine. This approval could potentially boost the company's vaccine distribution and sales in Taiwan.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 1:04 pm

Novavax Inc (NASDAQ:NVAX) shares hit a new 52-week low of $5.08, dropping 4.4% amid broader declines in COVID vaccine stocks following Pfizer Inc.'s FY24 guidance. Pfizer's forecast suggests a potential saturation in the COVID vaccine market, which could imply slower growth or lower revenues for other vaccine manufacturers like Novavax. Pfizer's guidance includes projections from the Seagen Inc acquisition but still falls short of the consensus estimate of $63.17 billion.

Portfolio Pulse from Henry Khederian

December 13, 2023 | 7:15 pm

Jim Cramer, on CNBC's 'Mad Money Lightning Round,' labeled Camtek Ltd. as 'too expensive' and advised waiting for a pullback. He expressed a longstanding dislike for Novavax, Inc., preferring Nucor Corporation over Atkore Inc. for steel-related investments. Cramer also deemed Coinbase Global, Inc. as 'too expensive' and suggested caution with EyePoint Pharmaceuticals, Inc. as 'the easy money has been made.' He compared American Eagle Outfitters, Inc. favorably to Abercrombie & Fitch Co., which he considers 'much better.'

Portfolio Pulse from Avi Kapoor

December 08, 2023 | 2:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.